

For Public Release

NZX Limited
Wellington

20 August 2024

Cannasouth Announces Resignation and Appointment of Directors for five Subsidiaries

Cannasouth Limited (NZX:CBD) announces the appointment of David Petterson as a director of the following subsidiaries:

1. Cannasouth Cultivation Limited;
2. Eqalis Group New Zealand Limited;
3. Eqalis Innovations Limited;
4. Eqalis Pharmaceuticals Limited; and
5. Restoreme Clinic Limited,

and that Mark Lucas and Colin Foster are no longer directors of those companies.

The above changes are effective from 16 August 2024.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Garry Whimp

Administrator, Blacklock Rose Ltd
Email: gwhimp@blr.co.nz
Mobile: 021 587 230

Ben Francis

Administrator, Blacklock Rose Ltd
Email: bfrancis@blr.co.nz
Mobile: 021 042 6991

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>